Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b for Antiangiogenic/Antivascular Effect in Adult Advanced Neoplasm
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Estimation of the toxicity of the combination of continuous low doses of Vinorelbine, Cyclophosphamide and Interferon alpha 2b.
6 weeks
Yes
Anthony GONCALVES, MD
Principal Investigator
Institut Paoli-Calmettes
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
METRO1/IPC2005-001
NCT00908869
May 2006
May 2011
Name | Location |
---|